Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.44 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.41 |
| ▸ | GGT1 | P19440 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28431532 | 1.00 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL21059082 | 1.00 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL196695 | 0.97 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL197139 | 0.97 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL197117 | 0.97 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Ammonia Solution, Strong SCHEMBL28728215 | 0.95 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Chloromethane SCHEMBL29259265 | 0.95 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL4576488 | 0.87 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL27695113 | 0.87 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Leucine SCHEMBL9119565 | 0.85 | SLC7A5 (0.72) | SLC7A5GRIK1SLC1A2SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256297-B | Preparation method of N-Boc- (R) -2-amino-4, 4-dimethylpentanoic acid | 爱斯特（成都）生物制药股份有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-108484661-B | Hexavanadic acid- β -alanine tert-butyl ester derivative and preparation method and application thereof | 湖北工业大学 | 2020-03-10 | — | — | CN | claimed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117136178-A | SARS-COV-2 Mpro inhibitor compounds | 赫帕雷斯治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-110256297-B | Preparation method of N-Boc- (R) -2-amino-4, 4-dimethylpentanoic acid | 爱斯特（成都）生物制药股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| EP-3724178-A1 | 1 -(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2020-10-01 | — | — | US | disclosed |
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| EP-3615019-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019118973-A1 | 1 -(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | WO | disclosed |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | US | disclosed |
| WO-2018200625-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| EP-3364958-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| CN-102149721-B | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS | 2015-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | PTGS1 509/4885GRIN2D 631/4885GRIN3B 1246/4885 |
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | PTGS1 509/4885GRIN2D 631/4885GRIN3B 1246/4885 |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | PTGS1 509/4885GRIN2D 631/4885GRIN3B 1246/4885 |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | PTGS1 509/4885GRIN2D 631/4885GRIN3B 1246/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | PTGS1 509/4885GRIN2D 631/4885GRIN3B 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.